{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"Research Square"}],"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:56:13Z","timestamp":1791219373433,"version":"4.1.0"},"posted":{"date-parts":[[2026,1,12]]},"group-title":"In Review","reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T00:00:00Z","timestamp":1768176000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2025,12,15]]},"abstract":"<title>Abstract<\/title>\n                <p>Purpose\n Continuous therapy in multiple myeloma (MM) can impose cumulative toxicities and psychosocial burden. This mixed\u2011methods study quantified patient preferences for treatment\u2011free intervals (TFIs), monitoring trade\u2011offs, and actionable service improvements across inpatient and outpatient care.\nMethods\n A 12-month, single-center mixed-methods survey (n\u2009=\u2009100) at a German tertiary center collected sociodemographics, treatment exposure, and structured items on TFI importance, preferred TFI length, monitoring intensity, relapse-risk trade-offs, inpatient stressors, and patient-generated improvement proposals. Quantitative analyses comprised descriptive statistics and hypothesis\u2011driven group comparisons; qualitative data were analyzed using inductive thematic analysis with double\u2011coding and consensus.\nResults\n TFIs between inpatient treatments were rated 10\/10 \u201cvery important\u201d by 49.5% and 0\/10 \u201cnot important\u201d by 9.1%. Predominant inpatient stressors were separation from family (27%), treatment\u2011related symptoms\/side effects (23%), fatigue (17%), food quality (15%), waiting times (14%), and shared rooms (12%). In the outpatient setting, 77% found regular check\u2011ups reassuring, while 13% found them burdensome. When trading TFI length against relapse risk, 67% prioritized risk minimization and 7% would accept higher risk for longer TFIs. Preferred minimal TFIs were &lt;\u20094 weeks (23%), 4\u20138 weeks (19%), and &gt;\u20098 weeks (39%). Narratives emphasized physical\/emotional recovery, autonomy, restoration of routines, and pragmatic levers (single rooms, better food, shorter waits, flexible scheduling, staffing).\nConclusion\n People living with MM value TFIs - especially post\u2011inpatient - for recovery, while favoring vigilant, risk\u2011adapted monitoring. Preference\u2011sensitive TFI planning with explicit safety triggers and hybrid in\u2011person\/telehealth follow\u2011up may enhance quality of life without compromising safety.<\/p>","DOI":"10.21203\/rs.3.rs-8366273\/v1","type":"posted-content","created":{"date-parts":[[2026,1,12]],"date-time":"2026-01-12T05:50:03Z","timestamp":1768197003000},"source":"Crossref","is-referenced-by-count":0,"title":["Patient Preferences for Treatment\u2011Free Intervals in Multiple Myeloma: Mixed\u2011Methods Insights on Monitoring Trade\u2011offs and Supportive Care Improvements"],"prefix":"10.21203","author":[{"given":"Anna","family":"Fleischer","sequence":"first","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Barakat","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Peter","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie-Katrin","family":"Kadel","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Riedhammer","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick-Pascal","family":"Strunz","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Mersi","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Waldschmidt","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K. Martin","family":"Kort\u00fcm","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Einsele","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Maatouk","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo","family":"Rasche","sequence":"additional","affiliation":[{"name":"University Hospital W\u00fcrzburg"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"issue":"14","key":"ref1","doi-asserted-by":"crossref","first-page":"12897","DOI":"10.1007\/s00432-023-05137-8","article-title":"A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials","volume":"149","author":"Fleischer A","year":"2023","unstructured":"Fleischer, A., et al., A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials. J Cancer Res Clin Oncol, 2023. 149(14): p. 12897\u201312902.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"ref2","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1111\/ejh.14392","article-title":"Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes","volume":"114","author":"Perrot A","year":"2025","unstructured":"Perrot, A., et al., Sustained Improvement in Health-Related Quality of Life in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient-Reported Outcomes. Eur J Haematol, 2025. 114(5): p. 883\u2013889.","journal-title":"Eur J Haematol"},{"issue":"10","key":"ref3","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1111\/imj.70148","article-title":"Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia","volume":"55","author":"McCaughan G","year":"2025","unstructured":"McCaughan, G., et al., Management of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplantation: position statement of the Medical and Scientific Advisory Group of Myeloma Australia. Intern Med J, 2025. 55(10): p. 1741\u20131751.","journal-title":"Intern Med J"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1186\/s12885-025-15083-y","article-title":"Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework","volume":"25","author":"Boccadoro M","year":"2025","unstructured":"Boccadoro, M., et al., Supporting treatment decision-making for patients with multiple myeloma post-DRd in Italy: a multi-criteria decision framework. BMC Cancer, 2025. 25(1): p. 1676.","journal-title":"BMC Cancer"},{"issue":"2","key":"ref5","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s11523-024-01122-4","article-title":"Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options","volume":"20","author":"Mettias S","year":"2025","unstructured":"Mettias, S., et al., Multiple Myeloma: Improved Outcomes Resulting from a Rapidly Expanding Number of Therapeutic Options. Target Oncol, 2025. 20(2): p. 247\u2013267.","journal-title":"Target Oncol"},{"issue":"12","key":"ref6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009174","article-title":"Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies","volume":"12","author":"Fleischer A","year":"2024","unstructured":"Fleischer, A., et al., Neuropsychiatric manifestations following chimeric antigen receptor T cell therapy for cancer: a systematic review of clinical outcomes and management strategies. J Immunother Cancer, 2024. 12(12).","journal-title":"J Immunother Cancer"},{"issue":"23","key":"ref7","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1182\/blood.2024024582","article-title":"Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses","volume":"144","author":"Ailawadhi S","year":"2024","unstructured":"Ailawadhi, S., et al., Ide-cel vs standard regimens in triple-class-exposed relapsed and refractory multiple myeloma: updated KarMMa-3 analyses. Blood, 2024. 144(23): p. 2389\u20132401.","journal-title":"Blood"},{"issue":"16","key":"ref8","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1158\/1078-0432.CCR-24-4181","article-title":"FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma","volume":"31","author":"Sharma P","year":"2025","unstructured":"Sharma, P., et al., FDA Approval Summary: Idecabtagene Vicleucel for the Treatment of Triple-Class-Exposed, Relapsed or Refractory Multiple Myeloma. Clin Cancer Res, 2025. 31(16): p. 3362\u20133367.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"ref9","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1007\/s12672-025-03432-z","article-title":"T cell redirecting therapy for relapsed multiple myeloma","volume":"16","author":"Tan MSY","year":"2025","unstructured":"Tan, M.S.Y., T. Hellou, and D. Dingli, T cell redirecting therapy for relapsed multiple myeloma. Discov Oncol, 2025. 16(1): p. 1573.","journal-title":"Discov Oncol"},{"issue":"1","key":"ref10","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(24)00320-X","article-title":"Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial","volume":"12","author":"Mina R","year":"2025","unstructured":"Mina, R., et al., Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. Lancet Haematol, 2025. 12(1): p. e45\u2013e56.","journal-title":"Lancet Haematol"},{"issue":"7","key":"ref11","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1007\/s12325-025-03205-8","article-title":"Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison","volume":"42","author":"Puig N","year":"2025","unstructured":"Puig, N., et al., Comparative Efficacy of Ciltacabtagene Autoleucel Versus Standard-of-Care Treatments for Patients with Previously Treated Relapsed or Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison. Adv Ther, 2025. 42(7): p. 3223\u20133239.","journal-title":"Adv Ther"},{"issue":"1","key":"ref12","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S2352-3026(24)00320-X","article-title":"Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial","volume":"12","author":"Mina R","year":"2025","unstructured":"Mina, R., et al., Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial. The Lancet Haematology, 2025. 12(1): p. e45\u2013e56.","journal-title":"The Lancet Haematology"},{"issue":"25","key":"ref13","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1200\/JCO-25-00760","article-title":"Long-Term (\u2265\u20095-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma","volume":"43","author":"Jagannath S","year":"2025","unstructured":"Jagannath, S., et al., Long-Term (\u2265\u20095-Year) Remission and Survival After Treatment With Ciltacabtagene Autoleucel in CARTITUDE-1 Patients With Relapsed\/Refractory Multiple Myeloma. J Clin Oncol, 2025. 43(25): p. 2766\u20132771.","journal-title":"J Clin Oncol"},{"issue":"23","key":"ref14","doi-asserted-by":"crossref","first-page":"e71401","DOI":"10.1002\/cam4.71401","article-title":"Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose Melphalan","volume":"14","author":"Fleischer A","year":"2025","unstructured":"Fleischer, A., et al., Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose Melphalan. Cancer Med, 2025. 14(23): p. e71401.","journal-title":"Cancer Med"},{"issue":"14","key":"ref15","doi-asserted-by":"crossref","first-page":"12897","DOI":"10.1007\/s00432-023-05137-8","article-title":"A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials","volume":"149","author":"Fleischer A","year":"2023","unstructured":"Fleischer, A., et al., A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials. J Cancer Res Clin Oncol, 2023. 149(14): p. 12897\u201312902.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"10","key":"ref16","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1007\/s12325-025-03308-2","article-title":"Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma","volume":"42","author":"Touzeau C","year":"2025","unstructured":"Touzeau, C., et al., Comparative Effectiveness of Ciltacabtagene Autoleucel in CARTITUDE-4 Versus Real-World Physician's Choice of Therapy from the Flatiron Registry in Lenalidomide-Refractory Multiple Myeloma. Adv Ther, 2025. 42(10): p. 5023\u20135041.","journal-title":"Adv Ther"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/ejh.70025","article-title":"From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real-World Evidence","volume":"115","author":"Pleitez HG","year":"2025","unstructured":"Pleitez, H.G., et al., From Trials to Practice: A 2025 Review of Idecabtagene Vicleucel and Ciltacabtagene Autoleucel Efficacy Across Clinical Studies and Real-World Evidence. Eur J Haematol, 2025. 115(6): p. 533\u2013546.","journal-title":"Eur J Haematol"},{"key":"ref18","article-title":"Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma","author":"Costa LJ","year":"2025","unstructured":"Costa, L.J., et al., Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. N Engl J Med, 2025.","journal-title":"N Engl J Med"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8366273\/v1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8366273\/v1.html","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:00:12Z","timestamp":1791216012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.researchsquare.com\/article\/rs-8366273\/v1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,12]]},"references-count":18,"URL":"https:\/\/doi.org\/10.21203\/rs.3.rs-8366273\/v1","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1007\/s00520-026-11255-z","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2026,1,12]]},"subtype":"preprint"}}